Hankyel Park

Array ( [id] => 1588448 [patent_doc_number] => 06482614 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-11-19 [patent_title] => 'Stress proteins and uses therefor' [patent_app_type] => B1 [patent_app_number] => 09/468041 [patent_app_country] => US [patent_app_date] => 1999-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 11 [patent_no_of_words] => 12301 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/482/06482614.pdf [firstpage_image] =>[orig_patent_app_number] => 09468041 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4379642 [patent_doc_number] => 06277601 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-08-21 [patent_title] => 'Expression of a foamy virus envelope protein' [patent_app_type] => 1 [patent_app_number] => 9/457324 [patent_app_country] => US [patent_app_date] => 1999-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 10 [patent_no_of_words] => 11791 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 119 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/277/06277601.pdf [firstpage_image] =>[orig_patent_app_number] => 457324 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4403173 [patent_doc_number] => 06270975 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-08-07 [patent_title] => 'Group O HIV-1, fragments of such viruses, and uses thereof' [patent_app_type] => 1 [patent_app_number] => 9/444410 [patent_app_country] => US [patent_app_date] => 1999-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 7 [patent_no_of_words] => 13244 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/270/06270975.pdf [firstpage_image] =>[orig_patent_app_number] => 444410 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4407505 [patent_doc_number] => 06228616 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-05-08 [patent_title] => 'Human anion channel' [patent_app_type] => 1 [patent_app_number] => 9/443948 [patent_app_country] => US [patent_app_date] => 1999-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 8 [patent_no_of_words] => 17223 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/228/06228616.pdf [firstpage_image] =>[orig_patent_app_number] => 443948 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4376048 [patent_doc_number] => 06303347 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-10-16 [patent_title] => 'Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors' [patent_app_type] => 1 [patent_app_number] => 9/439839 [patent_app_country] => US [patent_app_date] => 1999-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51594 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 200 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/303/06303347.pdf [firstpage_image] =>[orig_patent_app_number] => 439839 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7644070 [patent_doc_number] => 06428968 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-08-06 [patent_title] => 'Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject' [patent_app_type] => B1 [patent_app_number] => 09/435797 [patent_app_country] => US [patent_app_date] => 1999-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 11512 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/428/06428968.pdf [firstpage_image] =>[orig_patent_app_number] => 09435797 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4239565 [patent_doc_number] => 06143876 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2000-11-07 [patent_title] => 'Antibodies directed against binding-associated epitopes' [patent_app_type] => 1 [patent_app_number] => 9/433420 [patent_app_country] => US [patent_app_date] => 1999-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 19 [patent_no_of_words] => 5466 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 149 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/143/06143876.pdf [firstpage_image] =>[orig_patent_app_number] => 433420 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1564760 [patent_doc_number] => 06338963 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-01-15 [patent_title] => 'Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis' [patent_app_type] => B1 [patent_app_number] => 09/420543 [patent_app_country] => US [patent_app_date] => 1999-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 53 [patent_figures_cnt] => 89 [patent_no_of_words] => 30042 [patent_no_of_claims] => 85 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/338/06338963.pdf [firstpage_image] =>[orig_patent_app_number] => 09420543 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4181270 [patent_doc_number] => 06159684 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2000-12-12 [patent_title] => 'HIV trans-activator TAT binding to CDK7 and activation of CTD phosphorylation' [patent_app_type] => 1 [patent_app_number] => 9/420081 [patent_app_country] => US [patent_app_date] => 1999-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 9362 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/159/06159684.pdf [firstpage_image] =>[orig_patent_app_number] => 420081 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4409475 [patent_doc_number] => 06172201 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-01-09 [patent_title] => 'Cellular receptor for HIV-1 Vpr essential for G2/M phase' [patent_app_type] => 1 [patent_app_number] => 9/418175 [patent_app_country] => US [patent_app_date] => 1999-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 20 [patent_no_of_words] => 11484 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/172/06172201.pdf [firstpage_image] =>[orig_patent_app_number] => 418175 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4402910 [patent_doc_number] => 06270959 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-08-07 [patent_title] => 'Human T-cell lymphotropic virus type II envelope protein and human monoclonal antibodies specific therefor' [patent_app_type] => 1 [patent_app_number] => 9/409025 [patent_app_country] => US [patent_app_date] => 1999-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 10 [patent_no_of_words] => 12357 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/270/06270959.pdf [firstpage_image] =>[orig_patent_app_number] => 409025 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1494970 [patent_doc_number] => 06342586 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-01-29 [patent_title] => 'Non-peptidyl moiety-conjugated CD4-gamma2 and CD4-IgG2 immunoconjugates and uses thereof' [patent_app_type] => B1 [patent_app_number] => 09/409006 [patent_app_country] => US [patent_app_date] => 1999-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 25823 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/342/06342586.pdf [firstpage_image] =>[orig_patent_app_number] => 09409006 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1580005 [patent_doc_number] => 06423308 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-07-23 [patent_title] => 'Treatment of Kaposi\'s sarcoma with IL-12' [patent_app_type] => B1 [patent_app_number] => 09/396931 [patent_app_country] => US [patent_app_date] => 1999-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13629 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/423/06423308.pdf [firstpage_image] =>[orig_patent_app_number] => 09396931 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4308510 [patent_doc_number] => 06316210 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-11-13 [patent_title] => 'Genetic suppressor elements against human immunodeficiency virus' [patent_app_type] => 1 [patent_app_number] => 9/388128 [patent_app_country] => US [patent_app_date] => 1999-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 11257 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/316/06316210.pdf [firstpage_image] =>[orig_patent_app_number] => 388128 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4364655 [patent_doc_number] => 06274343 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-08-14 [patent_title] => 'Vasopermeability enhancing immunoconjugates' [patent_app_type] => 1 [patent_app_number] => 9/382359 [patent_app_country] => US [patent_app_date] => 1999-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 11736 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/274/06274343.pdf [firstpage_image] =>[orig_patent_app_number] => 382359 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4320805 [patent_doc_number] => 06331403 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-12-18 [patent_title] => 'Use of mCRP to slow cell growth and to promote maturation of cells' [patent_app_type] => 1 [patent_app_number] => 9/376398 [patent_app_country] => US [patent_app_date] => 1999-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 8838 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/331/06331403.pdf [firstpage_image] =>[orig_patent_app_number] => 376398 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4380321 [patent_doc_number] => 06294370 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-09-25 [patent_title] => 'System for the production of AAV vectors' [patent_app_type] => 1 [patent_app_number] => 9/214151 [patent_app_country] => US [patent_app_date] => 1999-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3481 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/294/06294370.pdf [firstpage_image] =>[orig_patent_app_number] => 214151 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4308723 [patent_doc_number] => 06316223 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-11-13 [patent_title] => 'Mammalian protein interaction cloning system' [patent_app_type] => 1 [patent_app_number] => 9/359081 [patent_app_country] => US [patent_app_date] => 1999-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 15661 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 163 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/316/06316223.pdf [firstpage_image] =>[orig_patent_app_number] => 359081 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4316850 [patent_doc_number] => 06248515 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-06-19 [patent_title] => 'Methods for the early detection of HIV infection' [patent_app_type] => 1 [patent_app_number] => 9/351666 [patent_app_country] => US [patent_app_date] => 1999-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 6 [patent_no_of_words] => 6844 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/248/06248515.pdf [firstpage_image] =>[orig_patent_app_number] => 351666 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4308183 [patent_doc_number] => 06316190 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-11-13 [patent_title] => 'Oligonucleotides which specifically bind retroviral nucleocapsid proteins' [patent_app_type] => 1 [patent_app_number] => 9/180903 [patent_app_country] => US [patent_app_date] => 1999-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 20606 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/316/06316190.pdf [firstpage_image] =>[orig_patent_app_number] => 180903 [rel_patent_id] =>[rel_patent_doc_number] =>)